海南海药(000566) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥755,828,955.92, representing a 14.99% increase compared to ¥657,320,034.01 in the same period last year[8]. - The net profit attributable to shareholders was ¥73,294,437.05, a slight increase of 1.31% from ¥72,350,167.05 year-on-year[8]. - The net profit after deducting non-recurring gains and losses decreased by 3.59% to ¥64,122,311.88 from ¥66,510,693.01 in the previous year[8]. - The basic earnings per share remained unchanged at ¥0.05, with a diluted earnings per share also at ¥0.05[8]. - The weighted average return on net assets was 1.50%, slightly down from 1.51% in the previous year[8]. - The company's net profit margin decreased, with a net loss of ¥22,419,637.52 compared to a loss of ¥6,433,090.54 in the previous period[50]. - The net profit for the current period is ¥69,594,316.53, slightly down from ¥70,639,034.28, indicating a decrease of approximately 1.5%[58]. - The total profit for the current period is ¥72,134,064.40, down from ¥89,723,513.63 in the previous period, reflecting a decline of about 19.7%[58]. Cash Flow - The net cash flow from operating activities improved significantly, reaching -¥31,865,006.93, a 59.50% increase from -¥78,683,507.15 in the same period last year[8]. - The cash flow from operating activities is ¥518,335,248.20, compared to ¥543,992,734.37 in the previous period, showing a slight decrease[64]. - Total cash inflow from operating activities was 584,190,406.09, while cash outflow was 616,055,413.02, resulting in a net cash flow of -31,865,006.93[66]. - The net cash flow from financing activities was 352,688,023.08, a substantial increase compared to -77,985,028.33 in the prior period[68]. - The company reported a significant increase in cash received from operating activities, totaling 598,028,744.77 compared to 265,021,223.55 in the previous period[72]. - The company experienced a net increase in cash and cash equivalents of -113,406,927.79, compared to -672,175,188.83 in the previous period[68]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,914,737,218.59, up 5.60% from ¥10,336,406,520.68 at the end of the previous year[8]. - The total liabilities increased to ¥5,683,095,114.88 from ¥5,302,675,007.04, reflecting a rise of approximately 7.2%[36]. - The company's short-term borrowings increased to ¥2,285,297,543.59 from ¥1,985,300,000.00, marking an increase of about 15.1%[38]. - The total liabilities rose to ¥5,929,429,512.43, up from ¥5,510,976,501.58, representing an increase of approximately 7.6%[42]. - The total current liabilities include accounts payable and notes payable of ¥555,513,528.48[80]. Shareholder Information - The net assets attributable to shareholders increased by 3.40% to ¥4,764,998,890.78 from ¥4,608,365,842.41 at the end of the previous year[8]. - The total number of ordinary shareholders at the end of the reporting period was 61,799[13]. - The first employee stock ownership plan was fully sold, with 8,146,646 shares representing 0.61% of total equity[23]. - The second employee stock ownership plan was terminated as it did not complete stock purchases by the deadline[23]. Investments and Expenses - Research and development expenses were reported at ¥2,291,758.76, slightly higher than ¥2,116,673.73 in the previous period, indicating continued investment in innovation[51]. - Total financial expenses rose by 31.49% to ¥60,113,786.14, driven by increased loan interest expenses[21]. - Investment income decreased by 214.95% to -¥15,464,244.82, reflecting reduced returns from joint ventures[21]. - The company reported a significant increase in interest expenses, which rose to ¥73,577,197.49 from ¥60,470,880.58, highlighting rising borrowing costs[51]. Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥9,172,125.17 for the reporting period[11]. - The company has no derivative investments during the reporting period[29]. - The company has invested ¥249,692,653.71 in development expenditures, reflecting ongoing R&D efforts[78]. - The company reported a foreign exchange loss of ¥1,478,280.42, compared to a loss of ¥3,246,012.47 in the previous period[56].